Valuation: Nexstim Oyj

Market Cap 74.69M 86.07M 69.94M 63.98M 121M 8.2B 122M 818M 321M 4.1B 323M 316M 13.63B P/E 2026 *
77.1x
P/E 2027 * 34.3x
Enterprise Value 72.59M 83.65M 67.97M 62.18M 117M 7.97B 119M 795M 312M 3.98B 314M 307M 13.25B EV / Sales 2026 *
5.72x
EV / Sales 2027 * 4.41x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 10/02/2020
Director of Finance/CFO 40 10/02/2020
Chief Tech/Sci/R&D Officer 65 31/12/2007
Director TitleAgeSince
Director/Board Member 64 10/11/2019
Chairman 63 10/11/2019
Director/Board Member 55 30/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-5.73% - - 86.24M
-0.74%-0.60%+27.71%+3.90% 214B
-1.02%+0.44%+0.96%-22.92% 140B
-0.28%+5.71%-21.29%+20.65% 133B
+3.83%+7.29%-52.06%-2.71% 69.19B
-0.20%+1.67%+12.42%+10.68% 51.28B
-0.36%+5.11%-14.27%-19.86% 50.43B
-0.80%+0.78%+23.46%+10.50% 39.85B
-0.97%+3.94%+42.33%+36.43% 39.27B
+0.05%+7.08%-20.37%+19.63% 32.32B
Average -0.72%+3.77%-0.13%+6.26% 85.43B
Weighted average by Cap. -0.21%+3.04%+1.93%+2.86%

Financials

2026 *2027 *
Net sales 12.7M 14.63M 11.89M 10.88M 20.54M 1.39B 20.8M 139M 54.6M 697M 54.95M 53.75M 2.32B 16.1M 18.55M 15.08M 13.79M 26.03M 1.77B 26.37M 176M 69.22M 883M 69.66M 68.14M 2.94B
Net income 1M 1.15M 936K 857K 1.62M 110M 1.64M 10.95M 4.3M 54.84M 4.33M 4.23M 183M 2.2M 2.54M 2.06M 1.88M 3.56M 241M 3.6M 24.1M 9.46M 121M 9.52M 9.31M 402M
Net Debt -2.1M -2.42M -1.97M -1.8M -3.4M -231M -3.44M -23M -9.03M -115M -9.09M -8.89M -383M -3.7M -4.26M -3.46M -3.17M -5.98M -406M -6.06M -40.53M -15.91M -203M -16.01M -15.66M -675M
Logo Nexstim Oyj
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-